LLY compared with ALDX: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

ALDXAldeyra Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

ALDXAldeyra Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

ALDX

0 of 3at or beyond implied

Reportimpliedrealized× implied

May 4 '23±13.6%▲+2.06%×0.15

Mar 9 '23±7.5%▲+7.19%×0.96

= impliedLLY realized, solidALDX realized, hatchedOne scale, both sides: full bar = 20%× = |realized| ÷ impliedSource: market data

Nov 10 '22

—

▲+6.18%

—

Aug 5 '22±19.4%▲+10.90%×0.56

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,363.77

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

ALDXAldeyra Therapeutics, Inc.

0.61▼−5.53%· post 0.61

ClosedNov 5 '26

Mkt cap$39.1MRevenue—Revenue—

Compare

ClosedNov 5 '26

LLYELI Lilly & Co

ALDXAldeyra Therapeutics, Inc.

1,371.32▼−3.29%post 1,363.77

Price

0.61▼−5.53%post 0.61

$1.2T

Mkt cap

$39.1M

Q3 FY26$24.4B

Revenue

—

FY25$65.2B

Revenue

—

LLY1,371.32▼−3.29%vsALDX0.61▼−5.53%ClosedNov 5 '26